Supply of Paracetamol Osteo-Tab 665 mg modified release tablet blister pack and bottle by AFT Pharmaceuticals

Overview

The Therapeutic Goods Act 1989 (TGA) was enacted to regulate therapeutic goods in Australia, ensuring that these products are safe, of acceptable quality, and their benefits outweigh any risks. This legislation was introduced to address the need for a comprehensive framework governing the manufacturing, advertising, and distribution of therapeutic goods. The TGA is administered by the Parliament of Australia, with the primary policy objective of protecting public health by ensuring that only therapeutic goods that meet safety, quality, and efficacy standards are available for use in Australia. This is achieved through rigorous assessment and oversight processes, including the ability to grant exemptions from certain regulatory requirements under specific conditions, as demonstrated by the consent issued for Paracetamol Osteo-Tab 665 mg modified release tablets. This consent, issued by a delegate of the Secretary to the Department of Health and Ageing, allows for the supply of products that do not fully meet certain pharmacopoeia standards, provided all other quality requirements are satisfied.

Scope and Application

The Therapeutic Goods Act 1989 (the Act) applies to a wide range of entities and individuals involved in the regulation and distribution of therapeutic goods in Australia. This includes pharmaceutical companies, healthcare providers, and manufacturers, all of whom must comply with the regulatory standards set forth by the Act. The Act applies nationally across Australia, covering all states and territories, thereby establishing a unified regulatory framework for therapeutic goods. The Act's scope encompasses the approval, advertising, supply, and monitoring of therapeutic goods, ensuring that they meet safety, quality, and efficacy standards. The Act also allows for certain exclusions and exemptions, which may apply to specific goods or circumstances as outlined in the legislation or through subordinate instruments. In the provided notice, the delegate of the Secretary has granted specific consent to AFT Pharmaceuticals to supply certain paracetamol products that do not fully comply with US Pharmacopoeia standards, subject to conditions ensuring compliance with other regulatory requirements. This demonstrates the Act's flexibility in accommodating specific cases while maintaining overarching regulatory oversight.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) allow for the granting of consent by a delegate of the Secretary to the Department of Health and Ageing to supply therapeutic goods that do not fully comply with specified standards. In this instance, Section 14 consent is given to AFT Pharmaceuticals to supply Paracetamol Osteo-Tab 665 mg modified release tablet blister packs and bottles (AUST R 202406 and AUST R 202407 respectively) which do not meet the US Pharmacopoeia monograph for Acetaminophen Extended Release Tablets regarding dissolution tests and limits (section 14(1)). However, this consent is conditional upon the product meeting all other aspects of the standard (section 14(2)). The obligations imposed by this consent are primarily on AFT Pharmaceuticals. They must ensure that the supplied product adheres to all aspects of the standard except for the specified dissolution tests and limits. This involves maintaining rigorous quality control processes to verify that the product meets the stipulated conditions and does not pose any risks to public health. Additionally, AFT Pharmaceuticals must keep records and documentation demonstrating compliance with these conditions, which may be subject to inspection by regulatory authorities. Failure to comply with the conditions outlined in the consent can lead to serious consequences. Under section 15(2) of the Act, breaches of the conditions can result in the consent being revoked. This revocation means that the non-compliant product can no longer be supplied, potentially leading to significant commercial and operational disruptions for AFT Pharmaceuticals. Additionally, the Act provides for both civil and criminal penalties for non-compliance with its provisions. For example, section 33DA imposes fines for supplying non-compliant therapeutic goods, with the maximum penalty being $22,200 for individuals and substantially higher for corporations. These penalties underscore the importance of adhering to the regulatory framework and the potential ramifications of non-compliance.